XML 111 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Share-based Payments
 3 Months Ended
Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based Payments
Share-based Payments
Share-based Compensation Expense
The following table summarizes share-based compensation expense included within our condensed consolidated statements of income:
 
For the Three Months
Ended March 31,
(In millions)
2015
 
2014
Research and development
$
35.4

 
$
29.4

Selling, general and administrative
55.6

 
47.2

Subtotal
91.0

 
76.6

Capitalized share-based compensation costs
(3.4
)
 
(2.6
)
Share-based compensation expense included in total cost and expenses
87.6

 
74.0

Income tax effect
(26.7
)
 
(22.3
)
Share-based compensation expense included in net income attributable to Biogen Inc.
$
60.9

 
$
51.7


The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:
 
For the Three Months
Ended March 31,
(In millions)
2015
 
2014
Market stock units
$
17.0

 
$
14.9

Time-vested restricted stock units
31.9

 
29.2

Cash settled performance units
23.8

 
21.4

Performance units
13.2

 
6.3

Employee stock purchase plan
5.1

 
4.8

Subtotal
91.0

 
76.6

Capitalized share-based compensation costs
(3.4
)
 
(2.6
)
Share-based compensation expense included in total cost and expenses
$
87.6

 
$
74.0


Grants Under Share-based Compensation Plans
The following table summarizes our equity grants to employees, officers and directors under our current stock plans:
 
For the Three Months
Ended March 31,
 
2015
 
2014
Market stock units
175,000

 
214,000

Cash settled performance shares
112,000

 
172,000

Performance units
89,000

 
50,000

Time-vested restricted stock units
351,000

 
392,000


In addition, for the three months ended March 31, 2015, approximately 68,000 shares were issued under our employee stock purchase plan compared to approximately 74,000 shares issued in the prior year comparative period.